Novamind to Host MindMed Phase IIb Trial for LSD and Anxiety
Novamind (NM) announced that it will host MindMed’s (MMED) Phase IIb study on LSD for generalized anxiety disorder later this year. The trial will assess 200 patients for 12 weeks following a single dose of MindMed’ LSD formualtion.